Brain-derived neurotrophic factor (BDNF) has a neurotrophic support on neuron of central
nervous system (CNS) and is a key molecule in the maintenance of synaptic plasticity and …

Introduction: Phosphodiesterase (PDE) inhibitors improve signaling pathways in brain
circuits by increasing intracellular cyclic adenosine monophosphate (cAMP) and/or cyclic …

We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …

Alzheimer's disease (AD) is the most common form of dementia among the elderly. In AD
patients, memory loss is accompanied by the formation of beta-amyloid plaques and the …

Deficits in brain function that are associated with aging and age-related diseases benefit
very little from currently available therapies, suggesting a better understanding of the …

The nitric oxide (NO)/cGMP pathway has been extensively studied for its pivotal role in
synaptic plasticity and memory processes, resulting in an increase of cAMP response …

Background: Preclinical studies, clinical trials, and reviews suggest increasing 3', 5'-cyclic
adenosine monophosphate (cAMP) and 3', 5'-cyclic guanosine monophosphate (cGMP) with …

Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing
the degradation of these cyclic nucleotides. Since both cAMP and cGMP signaling are …

Following two decades of more than 400 clinical trials centered on the “one drug, one target,
one disease” paradigm, there is still no effective disease‐modifying therapy for Alzheimer's …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …